Holly May
Corporate Officer/Principal presso BIOLINERX LTD.
Patrimonio netto: - $ in data 31/05/2024
Profilo
Holly W.
May is currently the President-BioLineRx USA at BioLineRx Ltd.
She previously worked as the Vice President-Sales & Marketing at Swedish Orphan Biovitrum AB from 2018 to 2019.
Before that, she held positions as the Chief Commercial Officer at Avrobio, Inc., Vice President & Head-Commercial at Sobi, Inc., Vice President at Genzyme Israel Ltd., and Head-Marketing Operations at Sanofi-Aventis Israël Ltd.
Ms. May holds an MBA from the University of Akron and an undergraduate degree from the University of Miami.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
BIOLINERX LTD.
-.--% | 15/03/2024 | 0 ( -.--% ) | - $ | 31/05/2024 |
Posizioni attive di Holly May
Società | Posizione | Inizio |
---|---|---|
BIOLINERX LTD. | Corporate Officer/Principal | 16/06/2022 |
Precedenti posizioni note di Holly May
Società | Posizione | Fine |
---|---|---|
SWEDISH ORPHAN BIOVITRUM AB | Vendite & Marketing | 01/08/2019 |
Sanofi-Aventis Israël Ltd. | Vendite & Marketing | - |
Genzyme Israel Ltd. | Corporate Officer/Principal | - |
Sobi, Inc. | Corporate Officer/Principal | - |
TECTONIC THERAPEUTIC, INC. | Corporate Officer/Principal | - |
Formazione di Holly May
University of Akron | Masters Business Admin |
University of Miami | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
BIOLINERX LTD. | Health Technology |
SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
Aziende private | 4 |
---|---|
Avrobio, Inc.
Avrobio, Inc. BiotechnologyHealth Technology AVROBIO, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firm's clinical-stage programs include Fabry, Gaucher Type 1, Hunter syndrome Gaucher Type 3, Pompe, and Cystinosis. The company was founded by Geoff Mackay, Kim Warren, Christopher Mason, and Jeffrey Medin in 2015 and is headquartered in Watertown, MA. | Health Technology |
Sanofi-Aventis Israël Ltd. | |
Sobi, Inc. | |
Genzyme Israel Ltd. |
- Borsa valori
- Insiders
- Holly May